In yesterday’s Wall Street session, aTyr Pharma Inc. (NASDAQ:LIFE) shares traded at $2.45, down -1.61% from the previous session.
As we calculate the median target price by taking the range between a high of $35.00 and a low of $10.00, we find $18.50. Given the previous closing price of $2.49, this indicates a potential upside of 642.97 percent. LIFE stock price is now 9.24% away from the 50-day moving average and -18.00% away from the 200-day moving average. The market capitalization of the company currently stands at $67.77M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Brokers who have rated the stock have averaged $19.50 as their price target over the next twelve months.
With the price target of $22, RBC Capital Mkts recently initiated with Outperform rating for aTyr Pharma Inc. (NASDAQ: LIFE). On September 21, 2021, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $19, while ‘Laidlaw’ rates the stock as ‘Buy’.
In other news, Shukla Sanjay, President and CEO bought 10,000 shares of the company’s stock on Nov 21. The stock was bought for $21,405 at an average price of $2.14. Upon completion of the transaction, the President and CEO now directly owns 50,798 shares in the company, valued at $0.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 01, President and CEO Shukla Sanjay bought 15,000 shares of the business’s stock. A total of $43,164 was incurred on buying the stock at an average price of $2.88. This leaves the insider owning 40,798 shares of the company worth $99955.1. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LIFE stock. A new stake in aTyr Pharma Inc. shares was purchased by WALLEYE CAPITAL LLC during the first quarter worth $997,000. BNP PARIBAS ARBITRAGE, SNC invested $4,000 in shares of LIFE during the first quarter. In total, there are 43 active investors with 70.70% ownership of the company’s stock.
On Thursday morning aTyr Pharma Inc. (NASDAQ: LIFE) stock kicked off with the opening price of $2.4900. During the past 12 months, aTyr Pharma Inc. has had a low of $2.00 and a high of $6.62. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 7.50, and a quick ratio of 7.50. The fifty day moving average price for LIFE is $2.2427 and a two-hundred day moving average price translates $2.9880 for the stock.
The latest earnings results from aTyr Pharma Inc. (NASDAQ: LIFE) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.44, missing analysts’ expectations of -$0.38 by -0.06. This compares to -$0.42 EPS in the same period last year. The company reported revenue of $13.49 million for the quarter, compared to $7.73 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 74.59 percent. For the current quarter, analysts expect LIFE to generate $330k in revenue.
aTyr Pharma Inc.(LIFE) Company Profile
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
